This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Alison Crawford, PhD
Senior Staff Scientist, Oncology and Angiogenesis at Regeneron Pharmaceuticals


Dr. Alison Crawford is a Senior Staff Scientist in the immune-oncology group at Regeneron Pharmaceuticals, Inc. She has >18 years of immunology research experience, including > 8 years in the pharmaceutical industry. At Regeneron Pharmaceuticals, her team is responsible for IND-enabling studies as well as mechanistic studies using bispecific antibodies for oncology indications. She led the in vivo pre-clinical research efforts on REGN4018 (MUC16xCD3) to advance the antibody through to IND submission. Dr. Crawford completed her BSc in Immunology from Glasgow University before being admitted to the Wellcome Trust Ph.D. program at Edinburgh University where she focused on T cell memory. Her post-doctoral work at the University of Pennsylvania examined T cell exhaustion during chronic viral infection and the use of checkpoint blockade to alleviate this exhaustion.

Agenda Sessions

  • Bispecific T cell Engagers

  • REGN4018 is a Mucin 16 Bispecific T cell–engaging Antibody for the Treatment of Ovarian Cancer

    On Demand